
Nidhi Jyotsana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8181684/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes. PLoS ONE, 2021, 16, e0246733.	2.5	7
2	Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia. Haematologica, 2020, 105, 1294-1305.	3.5	8
3	Fabrication and Characterization of Tumor Nano-Lysate as a Preventative Vaccine for Breast Cancer. Langmuir, 2020, 36, 6531-6539.	3.5	11
4	The Impact of COVID-19 on Cancer Risk and Treatment. Cellular and Molecular Bioengineering, 2020, 13, 285-291.	2.1	33
5	Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. Leukemia, 2020, 34, 2951-2963.	7.2	13
6	Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia. Cancers, 2020, 12, 2766.	3.7	29
7	Minimal dosing of leukocyte targeting TRAIL decreases triple-negative breast cancer metastasis following tumor resection. Science Advances, 2019, 5, eaaw4197.	10.3	50
8	Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo. Annals of Hematology, 2019, 98, 1905-1918.	1.8	61
9	Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer. Expert Opinion on Therapeutic Targets, 2018, 22, 107-121.	3.4	22
10	Fibulin-6 regulates pro-fibrotic TGF-β responses in neonatal mouse ventricular cardiac fibroblasts. Scientific Reports, 2017, 7, 42725.	3.3	15
11	miR-625-3p is upregulated in CD8+ T cells during early immune reconstitution after allogeneic stem cell transplantation. PLoS ONE, 2017, 12, e0183828.	2.5	10
12	Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening. Current Cancer Drug Targets, 2016, 16, 818-828.	1.6	17
13	Effective Treatment of Human CML By RNAi In Vivo in a Xenotransplantation Mouse Model. Blood, 2015, 126, 1261-1261.	1.4	2
14	Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. Haematologica, 2014, 99, 1456-1464.	3.5	26
15	A Novel Inhibitor of Mutant IDH1 Induces Differentiation in Vivo and Prolongs Survival in a Mouse Model of Leukemia. Blood, 2014, 124, 3598-3598.	1.4	8
16	The Metabolite R-2-Hydroxyglutarate (R2HG) Collaborates with HoxA9 to Induce Monocytic Leukemia. Blood, 2014, 124, 366-366.	1.4	1
17	High-Throughput Drug Screening Identifies Pyrimethamine As a Potent and Selective Inhibitor of Acute Myeloid Leukemia. Blood, 2014, 124, 2304-2304.	1.4	0
18	Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood, 2013, 122, 2877-2887.	1.4	186